Eric S. Daar, MD; Jens Lundgren, MD
Jointly provided by Partners for Advancing Clinical Education (PACE) and Integritas Communications.
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
Severe COVID-19 continues to plague patients at high risk, such as those with certain comorbid conditions or those who are immunocompromised. Clinicians struggle to remain up to date on evolving guidelines, treatment options, circulating subvariants, and strategies to address long COVID. In this circuit training activity – consisting of text, graphics, videos, and interactive components - Drs. Eric Daar and Jens Lundgren discuss diagnosis of severe COVID-19, clinical trial and real-world data of antivirals, corticosteroids, and other immunomodulators for use in patients hospitalized for COVID-19, the most up to date guidelines, and the potential link between persistent viral replication, severe COVID-19, and long COVID.
This activity is intended for US and ex-US-based hospitalists, pulmonologists, internal medicine, emergency medicine, and ID physicians, NPs, PAs, nurses, and clinical pharmacists who care for patients with COVID-19.
Upon completion of this activity, participants should be able to:
- Discuss recent clinical trial data and the current regulatory status for COVID-19 therapies used in hospitalized patients
- Incorporate supplemental oxygen and pharmacologic treatments for hospitalized patients according to guideline recommendations and disease severity
- Create strategies to minimize the effects of prolonged viral replication in patients with severe COVID-19
Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA (University of California, Los Angeles) Medical Center
Investigator, Lundquist Institute
Professor of Medicine
David Geffen School of Medicine at UCLA
Jens Lundgren, MD, DMSc
Professor of Infectious Diseases
Director, CHIP (Centre of Excellence for Health, Immunity and Infections)
Heart Centre and University of Copenhagen
Faculty and Disclosure of Conflicts of Interest
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Eric S. Daar, MD - Consultant Fees: Gilead, Merck; Contracted Research: Gilead, ViiV
Jens Lundgren, MD, DMSc - Nothing to disclose
The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The Integritas Communication planners and others have no relevant financial relationship(s) to disclose with ineligible companies.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Integritas Communications. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
PACE designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour(s).
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Instructions for Credit
In order to obtain your CE credit, please follow the steps below at the conclusion of the activity:
- Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
- Complete the Preactivity Questions.
- Review the activity content.
- Achieve a grade of at least 70% on the Postactivity Test Questions and complete the Evaluation.
PACE Contact Information
For additional information about the accreditation of this activity, please visit https://partnersed.com
Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.Begin Activity
credit amount 0.75
credit type CME/CE
Exercising Best Practices for Hospitalized Patients